[{"data":1,"prerenderedAt":207},["ShallowReactive",2],{"$fs6wv3hgwaf6z":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":50,"top_diseases":75,"top_companies":103,"key_results":131,"trends":196,"previous_editions":205,"comparison":136,"highlighted_classes":206},1,"chest-2025","CHEST","chest","CHEST Annual Meeting 2025",2025,"Pulmonology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},3609,729,116,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":4,"Phase 3":20},2,6,3,40,[22,26,30,32,35,38,40,42,45,47],{"name":23,"count":24,"share":25},"GR",48,7,{"name":27,"count":28,"share":29},"CYP51A1",33,5,{"name":31,"count":28,"share":29},"PDCD1",{"name":33,"count":34,"share":19},"PBP",25,{"name":36,"count":37,"share":17},"ADRB2",18,{"name":39,"count":37,"share":17},"IL13RA1",{"name":41,"count":37,"share":17},"IL4R",{"name":43,"count":44,"share":17},"CD20",16,{"name":46,"count":44,"share":17},"TNFA",{"name":48,"count":49,"share":17},"F10",14,[51,55,59,62,64,67,70,73],{"name":52,"count":53,"share":54},"Small molecules",505,69,{"name":56,"count":57,"share":58},"Monoclonal antibodies",150,21,{"name":60,"count":61,"share":29},"Peptides",38,{"name":63,"count":28,"share":29},"Non-antibody therapeutic proteins",{"name":65,"count":66,"share":17},"Carbohydrate, lipid and polymer therapeutics",12,{"name":68,"count":69,"share":4},"Blood, tissue and cell-derived products",9,{"name":71,"count":72,"share":4},"Non-radioactive imaging and contrast agents",8,{"name":74,"count":29,"share":4},"Bispecific antibodies",[76,78,81,85,88,91,94,96,99,101],{"name":77,"count":24,"share":25},"chronic obstructive pulmonary disease (COPD)",{"name":79,"count":80,"share":18},"asthma",43,{"name":82,"count":83,"share":84},"acute kidney failure (AKF)",30,4,{"name":86,"count":87,"share":84},"septic shock",29,{"name":89,"count":90,"share":19},"non-small cell lung cancer (NSCLC)",24,{"name":92,"count":93,"share":19},"Atrial fibrillation (AFib)",23,{"name":95,"count":93,"share":19},"type 2 diabetes mellitus (T2DM)",{"name":97,"count":98,"share":19},"acute respiratory distress syndrome (ARDS)",22,{"name":100,"count":98,"share":19},"pulmonary embolism (PE)",{"name":102,"count":58,"share":19},"pneumonia",[104,108,111,114,117,119,122,125,127,129],{"name":105,"count":106,"share":107},"Pfizer",80,11,{"name":109,"count":110,"share":25},"Merck",50,{"name":112,"count":113,"share":18},"GSK",44,{"name":115,"count":116,"share":18},"AstraZeneca",41,{"name":118,"count":116,"share":18},"Bristol Myers Squibb",{"name":120,"count":121,"share":84},"Bayer",32,{"name":123,"count":124,"share":84},"Genentech",31,{"name":126,"count":93,"share":19},"Sanofi",{"name":128,"count":98,"share":19},"Regeneron Pharmaceuticals",{"name":130,"count":98,"share":19},"Roche",[132,141,147,153,161,168,174,182,189],{"title":133,"drug":134,"company":136,"phase":137,"disease":138,"finding":139,"url":140},"Efficacy and safety of Brensocatib in patients with noncystic fibrosis bronchiectasis and comorbid COPD: a subgroup analysis of the ASPEN trial",{"name":135,"slug":135},"brensocatib",null,"Phase 3","bronchiectasis","Brensocatib prolonged time to first exacerbation in patients with\u002Fwithout COPD (hazard ratio [95% CI] with COPD: 10mg: 0.67 [0.43-1.06], 25mg: 0.92 [0.62-1.37]; without COPD: 10mg: 0.82 [0.69-0.97], 25mg: 0.80 [0.67-0.96]).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.07.097",{"title":142,"drug":143,"company":136,"phase":137,"disease":77,"finding":145,"url":146},"Exacerbation rates in COPD patients: a retrospective analysis of the nebulized once daily long-acting muscarinic antagonist revefenacin in a 52-WEEK safety study",{"name":144,"slug":144},"revefenacin","For the large subgroup not on LABA\u002FICS, estimated REV vs. TIO hazard ratios with 95% CIs were 0.65 (0.37, 1.10) for all events, and 0.50 (0.27, 0.90) for moderate or severe events.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.07.3058",{"title":148,"drug":149,"company":112,"phase":137,"disease":77,"finding":151,"url":152},"Mepolizumab significantly reduces and delays COPD exacerbations in a wide spectrum of patients: pooled Phase III trial RESULTS",{"name":150,"slug":150},"mepolizumab","The hazard of reaching a first exacerbation at any point over the 104-week period was significantly reduced by 20% with mepolizumab versus placebo (hazard ratio [95% CI]: 0.80 [0.70, 0.90]; p\u003C0.001).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.09.100",{"title":154,"drug":155,"company":136,"phase":137,"disease":158,"finding":159,"url":160},"The SynAIRgy trial: a 26-WEEK Phase 3, randomized, double-blind, placebo-controlled study of aroxybutynin and atomoxetine (AD109) in obstructive sleep apnea",{"name":156,"slug":157},"AD109","ad109","obstructive sleep apnea hypopnea syndrome (OSAHS)","Adverse events (AEs) were predominantly mild with ≥1 AE reported by 232 (71.4%) participants with AD109 and 151 (47.3%) with PBO.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.09.072",{"title":162,"drug":163,"company":136,"phase":137,"disease":165,"finding":166,"url":167},"Effect of nerandomilast in US patients with idiopathic pulmonary fibrosis: subgroup analysis of the FIBRONEER-IPF trial",{"name":164,"slug":164},"nerandomilast","idiopathic pulmonary fibrosis (IPF)","The most frequent adverse event was diarrhea, reported in 14.3%, 34.3% and 42.9% of patients in the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively, over 52 weeks.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.07.2043",{"title":169,"drug":170,"company":136,"phase":137,"disease":77,"finding":172,"url":173},"Efficacy of ensifentrine in patients with a history of COPD exacerbations and eosinophils less than 300 cells\u002FµL",{"name":171,"slug":171},"ensifentrine","Over 24 weeks, ensifentrine numerically reduced the rate of moderate\u002Fsevere exacerbations by 38% and the risk of moderate\u002Fsevere exacerbations by 37% vs placebo in this subgroup.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.07.3108",{"title":175,"drug":176,"company":136,"phase":178,"disease":179,"finding":180,"url":181},"Dupilumab vs omalizumab: greater lung function improvements in patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma (EVEREST) with dupilumab",{"name":177,"slug":177},"dupilumab","Phase 4","chronic rhinosinusitis with nasal polyps (CRSwNP)","At Week 12, dupilumab vs omalizumab significantly improved pre-bronchodilator FEF 25–75% (least squares mean difference vs omalizumab [95% confidence interval] by 209 mL\u002Fs), and improvements were sustained through Week 24 (199 mL\u002Fs).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.09.075",{"title":183,"drug":184,"company":136,"phase":186,"disease":165,"finding":187,"url":188},"A randomized, placebo-controlled, parallel-group phase 2B trial of nalbuphine extended-release for chronic cough in patients with idiopathic pulmonary fibrosis",{"name":185,"slug":185},"nalbuphine","Phase 2","At Week 6, there was a ≥75% reduction in cough count in 5.6%, 17.5%, 37.1%, and 43.2% of patients in the placebo and NAL ER 27-mg, 54-mg, and 108-mg dose groups, respectively ( P \u003C0.01 vs placebo for 54-mg and 108-mg dose groups).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.09.095",{"title":190,"drug":191,"company":136,"phase":193,"disease":165,"finding":194,"url":195},"A randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacodynamics of saracatinib in idiopathic pulmonary fibrosis",{"name":192,"slug":192},"saracatinib","Phase 1\u002F2","Saracatinib was well tolerated; serious adverse events occurred in 14.3% of each group.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chest.2025.09.097",{"summary":197,"bullets":199},[198],"Small molecules were the most frequent modality (69% of drug-linked abstracts). GR was the most frequent target (7%). Chronic obstructive pulmonary disease (COPD) was the most frequent disease (7%).",[200,201,202,203,204],"Pfizer had the largest company share (11% of drug-linked abstracts).","Monoclonal antibodies were the next most frequent modality (21%).","CYP51A1 and PDCD1 were the next most frequent targets (5% each).","Asthma was the next most frequent disease (6%).","Merck had the next largest company share (7%).",[],[],1793970603104]